Posts

Sandoz targets 100+ biosimilars by 2040 with new $300 million Slovenia facility

on

Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars

on

Roche sees receding biosimilar impact, but Vabysmo slump returns

on

Novo Nordisk and Alvotech Face Continued FDA Scrutiny at Plants Tied to Recent FDA Rejections

on

Sandoz Tests Direct‑to‑Consumer Sales With Omnitrope Growth Hormone Biosimilar

on

Lupin Receives U.S. FDA Approval for Ranluspec™ (ranibizumab) Injection: Interchangeable Biosimilar for Eye Diseases Now Cleared in the U.S.

on

KOL Insight – Psoriatic Arthritis (Recent Trends, June 2026)

on

Italy probes Biogen for allegedly hindering sales of rival's MS drug

on

Sun Pharma Strikes Biopharma's Largest Deal of 2026 with $11.75B Buyout of Organon

on

Amneal Inks $1.1B Kashiv Buyout to Pursue Biosimilar Market Leadership

on

Trump Administration's Drug Pricing Reforms and Pharmaceutical Industry Response in 2026

on

Sandoz Expands Biosimilar Collaboration with Samsung Bioepis, Targeting Takeda's Entyvio

on

Patent Expirations Drive Biopharma Toward a Tougher 2026 with Major Revenue Risks

on

Sandoz Reorganizes for Biosimilars 'Golden Decade' Amid Patent Cliff Opportunities

on

mAbxience and HP Drive the Use of Artificial Intelligence in Biomanufacturing and Biosimilar Development

on

Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Global Markets

on

Sandoz Launches Tyruko (Natalizumab-Sztn), First Tysabri Biosimilar, in US After JCV Assay Delays

on

FDA Reduces Regulatory Red Tape for Biosimilars

on

Unlocking Access: Navigating Pharma’s Regulatory Crossroads – Recent Updates (2025)

on

Celltrion Acquires Eli Lilly’s New Jersey Manufacturing Site for $330 Million

on